SCHEMBL29566752

SCHEMBL29566752

Cn1cc(S(=O)(=O)Nc2nc(Cl)cc(Oc3ccccc3)n2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HTR1A P08908 4/20 0.42
▸ HTR7 P34969 4/20 0.42
▸ PGR P06401 5/20 0.39
▸ TRIM24 O15164 1/20 0.39
▸ BRD1 O95696 1/20 0.39
▸ BRPF1 P55201 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ EGFR P00533 2/20 0.39
▸ FGFR1 P11362 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ GPR119 Q8TDV5 3/20 0.38
▸ SLC8A1 P32418 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309624 1.00 TSHR (0.43) TSHRSMN1; SMN2HTR1AHTR7PGR
SCHEMBL24309685 0.87 MAPT (0.47) TSHRSMN1; SMN2HTR1AHTR7CYP1A2
SCHEMBL29566336 0.85 DGAT2 (0.42) HTR1AHTR7EGFRALDH1A1HPGD
SCHEMBL24309631 0.85 DGAT2 (0.42) HTR1AHTR7EGFRALDH1A1HPGD
SCHEMBL24309266 0.84 NLRP3 (0.41) TSHRSMN1; SMN2HTR1AHTR7MAPT
SCHEMBL29566612 0.83 TSHR (0.43) TSHRSMN1; SMN2HTR1AHTR7TRIM24
SCHEMBL24310345 0.83 TSHR (0.43) TSHRSMN1; SMN2HTR1AHTR7TRIM24
SCHEMBL26807484 0.83 HTR1A (0.43) TSHRSMN1; SMN2HTR1AHTR7CYP1A2
SCHEMBL29567157 0.83 LTA4H (0.41) EGFR
SCHEMBL24309513 0.83 LTA4H (0.41) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback